Aethlon Medical, Inc. Announces Resignation of Richard H. Tullis from its Board of Directors
June 09, 2015 at 03:46 pm IST
Share
On June 4, 2015, Dr. Richard H. Tullis notified the Chief Executive Officer of Aethlon Medical, Inc. of his resignation from its board of directors, effective June 5, 2015. Dr. Tullis will continue in his position as the company's Chief Science Officer. Dr. Tullis resigned from the board so that the board would be constituted of a majority of independent directors, consistent with the corporate governance standards of the NASDAQ Capital Market.
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.